129 related articles for article (PubMed ID: 17073623)
1. Lentivirus-like particles without reverse transcriptase elicit efficient immune responses.
McBurney SP; Young KR; Nwaigwe CI; Soloff AC; Cole KS; Ross TM
Curr HIV Res; 2006 Oct; 4(4):475-84. PubMed ID: 17073623
[TBL] [Abstract][Full Text] [Related]
2. Membrane embedded HIV-1 envelope on the surface of a virus-like particle elicits broader immune responses than soluble envelopes.
McBurney SP; Young KR; Ross TM
Virology; 2007 Feb; 358(2):334-46. PubMed ID: 17011011
[TBL] [Abstract][Full Text] [Related]
3. Characterization of a DNA vaccine expressing a human immunodeficiency virus-like particle.
Young KR; Smith JM; Ross TM
Virology; 2004 Oct; 327(2):262-72. PubMed ID: 15351214
[TBL] [Abstract][Full Text] [Related]
4. Parainfluenza Virus 5 Priming Followed by SIV/HIV Virus-Like-Particle Boosting Induces Potent and Durable Immune Responses in Nonhuman Primates.
Xiao P; Dienger-Stambaugh K; Chen X; Wei H; Phan S; Beavis AC; Singh K; Adhikary NRD; Tiwari P; Villinger F; He B; Spearman P
Front Immunol; 2021; 12():623996. PubMed ID: 33717130
[TBL] [Abstract][Full Text] [Related]
5. HIV-1-based Virus-like Particles that Morphologically Resemble Mature, Infectious HIV-1 Virions.
Gonelli CA; Khoury G; Center RJ; Purcell DFJ
Viruses; 2019 Jun; 11(6):. PubMed ID: 31159488
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity of virus-like particles containing modified human immunodeficiency virus envelope proteins.
Quan FS; Sailaja G; Skountzou I; Huang C; Vzorov A; Compans RW; Kang SM
Vaccine; 2007 May; 25(19):3841-50. PubMed ID: 17320250
[TBL] [Abstract][Full Text] [Related]
7. Introducing a frameshift mutation to the POL sequence of HIV-1 provirus and evaluation of the immunogenic characteristics of the mutated virions (RINNL4-3).
Zabihollahi R; Sadat SM; Vahabpour R; Salehi M; Azadmanesh K; Siadat SD; Saraji AR; Pouriavali MH; Momen SB; Aghasadeghi MR
Mol Biol (Mosk); 2012; 46(3):519-24. PubMed ID: 22888641
[TBL] [Abstract][Full Text] [Related]
8. Rationally Designed Vaccines Targeting the V2 Region of HIV-1 gp120 Induce a Focused, Cross-Clade-Reactive, Biologically Functional Antibody Response.
Zolla-Pazner S; Powell R; Yahyaei S; Williams C; Jiang X; Li W; Lu S; Wang S; Upadhyay C; Hioe CE; Totrov M; Kong X
J Virol; 2016 Dec; 90(24):10993-11006. PubMed ID: 27630234
[TBL] [Abstract][Full Text] [Related]
9. Humoral immunity to HIV, SIV, and SHIV.
Haigwood NL; Zolla-Pazner S
AIDS; 1998; 12 Suppl A():S121-32. PubMed ID: 9632993
[No Abstract] [Full Text] [Related]
10. Control of simian/human immunodeficiency virus viremia and disease progression after IL-2-augmented DNA-modified vaccinia virus Ankara nasal vaccination in nonhuman primates.
Bertley FM; Kozlowski PA; Wang SW; Chappelle J; Patel J; Sonuyi O; Mazzara G; Montefiori D; Carville A; Mansfield KG; Aldovini A
J Immunol; 2004 Mar; 172(6):3745-57. PubMed ID: 15004179
[TBL] [Abstract][Full Text] [Related]
11. Effects of virus burden and chemokine expression on immunity to SHIV in nonhuman primates.
Waterman PM; Kitabwalla M; Hatfield GS; Evans PS; Lu Y; Tikhonov I; Bryant JL; Pauza CD
Viral Immunol; 2004; 17(4):545-57. PubMed ID: 15671751
[TBL] [Abstract][Full Text] [Related]
12. HIV-1 vaccines based on replication-competent Tiantan vaccinia protected Chinese rhesus macaques from simian HIV infection.
Liu Q; Li Y; Luo Z; Yang G; Liu Y; Liu Y; Sun M; Dai J; Li Q; Qin C; Shao Y
AIDS; 2015 Mar; 29(6):649-58. PubMed ID: 25849828
[TBL] [Abstract][Full Text] [Related]
13. Vaccination with the Conserved Caveolin-1 Binding Motif in Human Immunodeficiency Virus Type 1 Glycoprotein gp41 Delays the Onset of Viral Infection and Provides Partial Protection in Simian/Human Immunodeficiency Virus-Challenged Cynomolgus Macaques.
Hovanessian AG; Soundaramourty C; Benferhat R; Le Grand R; Dereuddre-Bosquet N; Krust B; Estaquier J
J Virol; 2018 Sep; 92(18):. PubMed ID: 29976675
[TBL] [Abstract][Full Text] [Related]
14. DNA vaccination of macaques by a full genome HIV-1 plasmid which produces noninfectious virus particles.
Akahata W; Ido E; Shimada T; Katsuyama K; Yamamoto H; Uesaka H; Ui M; Kuwata T; Takahashi H; Hayami M
Virology; 2000 Sep; 275(1):116-24. PubMed ID: 11017793
[TBL] [Abstract][Full Text] [Related]
15. Protective effects of nef-deleted SHIV or that having IFN-gamma against disease induced with a pathogenic virus early after vaccination.
Enose Y; Kita M; Yamamoto T; Suzuki H; Miyake A; Horiuchi R; Ibuki K; Kaneyasu K; Kuwata T; Takahashi E; Sakai K; Shinohara K; Miura T; Hayami M
Arch Virol; 2004 Sep; 149(9):1705-20. PubMed ID: 15593414
[TBL] [Abstract][Full Text] [Related]
16. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity.
Shiver JW; Fu TM; Chen L; Casimiro DR; Davies ME; Evans RK; Zhang ZQ; Simon AJ; Trigona WL; Dubey SA; Huang L; Harris VA; Long RS; Liang X; Handt L; Schleif WA; Zhu L; Freed DC; Persaud NV; Guan L; Punt KS; Tang A; Chen M; Wilson KA; Collins KB; Heidecker GJ; Fernandez VR; Perry HC; Joyce JG; Grimm KM; Cook JC; Keller PM; Kresock DS; Mach H; Troutman RD; Isopi LA; Williams DM; Xu Z; Bohannon KE; Volkin DB; Montefiori DC; Miura A; Krivulka GR; Lifton MA; Kuroda MJ; Schmitz JE; Letvin NL; Caulfield MJ; Bett AJ; Youil R; Kaslow DC; Emini EA
Nature; 2002 Jan; 415(6869):331-5. PubMed ID: 11797011
[TBL] [Abstract][Full Text] [Related]
17. Enhancement of cellular and humoral immune responses to human immunodeficiency virus type 1 Gag and Pol by a G/P-92 fusion protein expressing highly immunogenic Gag p17/p24 and Pol p51 antigens.
Kmieciak D; Bolesta E; Naito T; Gzyl J; Kaneko Y; Kozbor D
J Hum Virol; 2001; 4(6):306-16. PubMed ID: 12082397
[TBL] [Abstract][Full Text] [Related]
18. Qualitative T-helper responses to multiple viral antigens correlate with vaccine-induced immunity to simian/human immunodeficiency virus infection.
Mooij P; Nieuwenhuis IG; Knoop CJ; Doms RW; Bogers WM; Ten Haaft PJ; Niphuis H; Koornstra W; Bieler K; Köstler J; Morein B; Cafaro A; Ensoli B; Wagner R; Heeney JL
J Virol; 2004 Apr; 78(7):3333-42. PubMed ID: 15016855
[TBL] [Abstract][Full Text] [Related]
19. Protection of macaques against a SHIV with a homologous HIV-1 Env and a pathogenic SHIV-89.6P with a heterologous Env by vaccination with multiple gene-deleted SHIVs.
Ui M; Kuwata T; Igarashi T; Ibuki K; Miyazaki Y; Kozyrev IL; Enose Y; Shimada T; Uesaka H; Yamamoto H; Miura T; Hayami M
Virology; 1999 Dec; 265(2):252-63. PubMed ID: 10600597
[TBL] [Abstract][Full Text] [Related]
20. Protection of SIVmac-infected macaque monkeys against superinfection by a simian immunodeficiency virus expressing envelope glycoproteins of HIV type 1.
Dunn CS; Hurtrel B; Beyer C; Gloeckler L; Ledger TN; Moog C; Kieny MP; Mehtali M; Schmitt D; Gut JP; Kirn A; Aubertin AM
AIDS Res Hum Retroviruses; 1997 Jul; 13(11):913-22. PubMed ID: 9223407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
